Acute lymphoblastic leukemia - diagnosis and therapy
- 1 December 2019
- journal article
- research article
- Published by Hogrefe Publishing Group in Therapeutische Umschau
- Vol. 76 (9), 510-515
- https://doi.org/10.1024/0040-5930/a001127
Abstract
Acute lymphoblastic leukemia (ALL) is a rare malignant hematological disease. The incidence of the disease peaks in the childhood and thus is rare in adults, making assessment and care at qualified centers highly desirable. Clinically, ALL presents with the proliferation and accumulation of malignant, immature lymphatic blasts in the bone marrow, peripheral blood, and lymphatic and non-lymphatic tissue. Untreated, ALL results in death within few months. ALL is a heterogeneously disease. Prognosis is determined by immunophenotype, cytogenetics and molecular markers which influences therapeutic strategies. The aim of therapy in younger patients is curative. Patients should be treated in international study group protocols. Overall survival has improved over the last decade; also with the introduction of new targeted therapies. In addition, there have been recent developments in minimal / measurable residual disease (MRD) determination, which has a strong impact on the decision for an allogeneic hematopoietic stem cell transplantation.This publication has 22 references indexed in Scilit:
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic LeukemiaThe New England Journal of Medicine, 2016
- Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALLBlood, 2016
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Blinatumomab treatment of older adults with relapsed/refractory B‐precursor acute lymphoblastic leukemia: Results from 2 phase 2 studiesCancer, 2016
- Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2016
- Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologiesBlood, 2015
- Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemiaBlood, 2015
- Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemiaBlood, 2015
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2014
- Acute lymphoblastic leukaemiaThe Lancet, 2013